Literature DB >> 26849678

Marginally low birthweight increases the risk of underweight and short stature at three and a half years of age.

Staffan K Berglund1, Berit Kriström1, Matias Björn1, Josefine Lindberg1, Björn Westrup2, Mikael Norman3, Magnus Domellöf1.   

Abstract

AIM: Little is known about the long-term health of marginally low birthweight (LBW) children. This study characterised growth among infants weighing 2000 g-2500 g and explored the prevalence and predictors of sustained growth restriction.
METHOD: This prospective observational trial followed the weight and height of 281 Swedish marginally LBW children from birth to 3.5 years of age. Children with a standard deviation score (SDS) for body mass index or height below -2 were considered underweight and short, respectively.
RESULTS: The mean SDS for weight and height showed a rapid increase before 12-19 weeks of age. The most rapid weight gain was in infants born small for gestational age. However, at 3.5 years of age, 9.5% of the children remained underweight and 6.5% had short stature. Regression models showed that slow weight gain before 19 weeks of age was the strongest predictor for lasting underweight, while slow height gain before 19 weeks of age and male sex were associated with short stature.
CONCLUSION: Marginally LBW infants were more likely to be underweight and have a short stature at 3.5 years of age and the absence of catch-up growth during the first five months after birth identified those at highest risk. ©2016 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Catch-up growth; Growth velocity; Height; Preterm infant; Small for gestational age

Mesh:

Year:  2016        PMID: 26849678     DOI: 10.1111/apa.13356

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  1 in total

1.  Cardiometabolic risk factors in children born with marginally low birth weight: A longitudinal cohort study up to 7 years-of-age.

Authors:  Josefine Starnberg; Mikael Norman; Björn Westrup; Magnus Domellöf; Staffan K Berglund
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.